Combination Of A 4-Pyrimidinesulfamide Derivative With An Sglt-2 Inhibitor For The Treatment Of Endothelin Related Diseases

Patent No. EP3716979 (titled "Combination Of A 4-Pyrimidinesulfamide Derivative With An Sglt-2 Inhibitor For The Treatment Of Endothelin Related Diseases") was filed by Idorsia Pharmaceuticals on Nov 29, 2018. The application was issued on Apr 9, 2025.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ELKINGTON AND FIFEJan 8, 2026ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3716979

IDORSIA PHARMACEUTICALS
Application Number
EP18814821A
Filing Date
Nov 29, 2018
Status
Granted And Under Opposition
Mar 7, 2025
Publication Date
Apr 9, 2025